Stoke Therapeutics is a biotechnology company focused on developing innovative treatments for severe diseases by addressing their underlying causes. Utilizing a proprietary platform called TANGO (Targeted Augmentation of Nuclear Gene Output), Stoke aims to enhance protein output from healthy genes, particularly for conditions associated with haploinsufficiencies—where normal protein levels are significantly reduced. The company's initial focus is on diseases affecting the central nervous system and the eye, with investigational therapies like STK001 for Dravet syndrome and STK002 for autosomal dominant optic atrophy in clinical development. Stoke's culture prioritizes collaboration, innovation, and diversity, which are driven by their commitment to creating meaningful medicines for patients in need. With a robust values framework, Stoke fosters an inclusive environment where employees can thrive while playing a vital role in advancing groundbreaking science.